ArticleJournal of orthopaedic surgery and research2023
Survival benefits and challenges of adjuvant chemotherapy for high-grade osteosarcoma: a population-based study.
Article in Journal of orthopaedic surgery and research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 9 citations in OpenAlex.
- Nitrogen-doped carbon nanodots as a biocompatible FRET donor for caspase-3 detection and chemotherapy response evaluation in osteosarcoma cell lysates.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2026Article
- Immunotherapy combined with anti-angiogenic therapy, radiotherapy and chemotherapy for the treatment of giant pelvic osteosarcoma: A case report and literature review.Oncology letters · 2026Article
- Juglone induces GSDME axis pyroptosis in osteosarcoma cells via the JNK/P38 MAPK pathway.Scientific reports · 2026Article
- Circular RNAs in osteosarcoma: mechanistic insights, autophagy regulation, and potential therapeutic strategies.Cancer cell international · 2026Review
- Acetylshikonin induces ferroptosis via the lipid peroxidation pathway in osteosarcoma cells.Molecular medicine reports · 2026Article
- IGLC1 is an independent prognostic marker and potent therapeutic target in osteosarcoma.Discover oncology · 2025Article
- RBM15-mediated the m6A modification of MAT2A promotes osteosarcoma cell proliferation, metastasis and suppresses ferroptosis.Molecular and cellular biochemistry · 2025Article
- Malignant sarcomatous transformation of calvarial fibrous dysplasia: illustrative case.Journal of neurosurgery. Case lessons · 2024Article
- Cytotoxicity Enhancement in Osteosarcoma with Multifunctional I-131 Radiotherapeutic Nanoparticles: In Vitro Three-Dimensional Spheroid Model and Release Kinetics Modeling.Molecules (Basel, Switzerland) · 2024Article
- Correction: Survival benefits and challenges of adjuvant chemotherapy for high-grade osteosarcoma: a population-based study.Journal of orthopaedic surgery and research · 2023Article
- Extracellular Vesicles Derived From 3D Cultured Antler Stem Cells Serve as a New Drug Vehicle in Osteosarcoma Treatment.Cell transplantationArticle
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundOsteosarcoma is the most prevalent primary malignant bone tumor. The primary treatment for osteosarcoma is a combination of chemotherapy and surgery. However, there has been no recent progress in the role of chemotherapy in improving the long-term survival of osteosarcoma patients. This study aims to analyze the factors that affect chemotherapy in patients with osteosarcoma and explore the challenges and survival benefits of chemotherapy.
methodsPatient data were downloaded from The Surveillance, Epidemiology, and End Results database. Univariable and multivariable logistic regressions were used to analyze the factors affecting patients receiving chemotherapy. Kaplan-Meier (K-M) curve was used to analyze the survival benefit of chemotherapy in patients with osteosarcoma. Finally, we used annual percentage change (APC) to evaluate the annual changes in chemotherapy treatment rates and trends in 5-year survival rates in osteosarcoma patients.
resultsA total of 2157 osteosarcoma patients were included, of which 1887 patients received chemotherapy. Factors affecting patients receiving chemotherapy included age, primary tumor site, tumor size, N stage, M stage, and surgery. The K-M curve showed that older patients could benefit significantly from chemotherapy. The APC results showed no significant change in the chemotherapy treatment rate and 5-year overall survival rate of osteosarcoma patients.
conclusionChemotherapy is an irreplaceable treatment for patients with osteosarcoma. However, in recent years, there has been no significant progress in chemotherapy for osteosarcoma, and the long-term survival of patients has not improved significantly. New chemotherapeutic drugs or drug delivery systems are urgently needed to improve the prognosis of patients with osteosarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.